396 related articles for article (PubMed ID: 22172829)
21. Graft function based on two hours peak level monitoring of cyclosporine A during the first six months of renal transplantation.
Hami M; Naghibi M; Mojahedi MJ; Sharifipour F; Shakeri MT
Saudi J Kidney Dis Transpl; 2012 Nov; 23(6):1169-74. PubMed ID: 23168844
[TBL] [Abstract][Full Text] [Related]
22. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
Troncoso P; Ortiz AM; Jara A; Vilches S
Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
[TBL] [Abstract][Full Text] [Related]
23. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
Midtvedt K; Fauchald P; Bergan S; Høieggen A; Hallan S; Svarstad E; Bergrem H; Eriksen BO; Pfeffer PF; Dalen I; Leivestad T
Transplantation; 2003 Oct; 76(8):1236-8. PubMed ID: 14578761
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of generic cyclosporine arpimune in Filipino low-risk primary kidney transplant recipients.
Pamugas GE; Danguilan RA; Lamban AB; Mangati VB; Ona ET
Transplant Proc; 2012 Jan; 44(1):101-8. PubMed ID: 22310590
[TBL] [Abstract][Full Text] [Related]
25. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
[TBL] [Abstract][Full Text] [Related]
26. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients.
Cole E; Maham N; Cardella C; Cattran D; Fenton S; Hamel J; O'Grady C; Smith R
Transplantation; 2003 Jun; 75(12):2086-90. PubMed ID: 12829917
[TBL] [Abstract][Full Text] [Related]
27. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
Carstens J
Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
[TBL] [Abstract][Full Text] [Related]
28. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
29. Long-term comparative results of C0 and C2 monitoring of CyA in renal transplanted patients.
Paydaş S; Balal M; Sertdemir Y; Seyrek N; Karayaylali I
Ren Fail; 2005; 27(4):409-13. PubMed ID: 16060128
[TBL] [Abstract][Full Text] [Related]
30. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
[TBL] [Abstract][Full Text] [Related]
31. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
[TBL] [Abstract][Full Text] [Related]
32. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
Caforio AL; Tona F; Piaserico S; Gambino A; Feltrin G; Fortina AB; Angelini A; Alaibac M; Bontorin M; Calzolari D; Peserico A; Thiene G; Iliceto S; Gerosa G
Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
[TBL] [Abstract][Full Text] [Related]
33. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
34. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole.
Videla C; Vega J; Borja H
Transplant Proc; 2005 Apr; 37(3):1574-6. PubMed ID: 15866677
[TBL] [Abstract][Full Text] [Related]
35. Can cyclosporine blood level be reduced to half after heart transplantation?
Wang SS; Chou NK; Chi NH; Huang SC; Wu IH; Wang CH; Yu HY; Chen YS; Tsao CI; Ko WJ; Shun CT
Transplant Proc; 2010 Apr; 42(3):930-3. PubMed ID: 20430207
[TBL] [Abstract][Full Text] [Related]
36. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
[TBL] [Abstract][Full Text] [Related]
37. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
Davies RA; Veinot JP; Williams K; Haddad H; Baker A; Donaldson J; Pugliese C; Struthers C; Masters RG; Hendry PJ; Mesana T
Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
[TBL] [Abstract][Full Text] [Related]
38. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine.
Hecking M; Kainz A; Schillinger M; Posch C; Birsan T; Rasoul-Rockenschaub S; Böhmig GA; Schmaldienst S; Watschinger B; Hörl WH; Mühlbacher F; Säemann MD
Transpl Int; 2008 Mar; 21(3):223-33. PubMed ID: 17903183
[TBL] [Abstract][Full Text] [Related]
39. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation].
Vavić N; Ignjatović L; Drasković B; Hrvacević R; Kovacević Z; Paunić Z
Vojnosanit Pregl; 2008 Feb; 65(2):119-27. PubMed ID: 18365668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
